EP4463456A4 - THIAZOLOPYRIDYLAMIDE DERIVATIVES AS DNA POLYMERASE ANTA INHIBITORS - Google Patents

THIAZOLOPYRIDYLAMIDE DERIVATIVES AS DNA POLYMERASE ANTA INHIBITORS

Info

Publication number
EP4463456A4
EP4463456A4 EP23740050.2A EP23740050A EP4463456A4 EP 4463456 A4 EP4463456 A4 EP 4463456A4 EP 23740050 A EP23740050 A EP 23740050A EP 4463456 A4 EP4463456 A4 EP 4463456A4
Authority
EP
European Patent Office
Prior art keywords
thiazolopyridylamide
anta
inhibitors
derivatives
dna polymerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23740050.2A
Other languages
German (de)
French (fr)
Other versions
EP4463456A1 (en
Inventor
Jing Li
Wenqing Xu
Zhiwei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines I GmbH
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of EP4463456A1 publication Critical patent/EP4463456A1/en
Publication of EP4463456A4 publication Critical patent/EP4463456A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP23740050.2A 2022-01-12 2023-01-11 THIAZOLOPYRIDYLAMIDE DERIVATIVES AS DNA POLYMERASE ANTA INHIBITORS Pending EP4463456A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022071563 2022-01-12
PCT/CN2023/071799 WO2023134708A1 (en) 2022-01-12 2023-01-11 Thiazolopyridyl amide derivatives as dna polymerase theta inhibitors

Publications (2)

Publication Number Publication Date
EP4463456A1 EP4463456A1 (en) 2024-11-20
EP4463456A4 true EP4463456A4 (en) 2025-10-29

Family

ID=87280119

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23740050.2A Pending EP4463456A4 (en) 2022-01-12 2023-01-11 THIAZOLOPYRIDYLAMIDE DERIVATIVES AS DNA POLYMERASE ANTA INHIBITORS

Country Status (6)

Country Link
US (1) US20250026766A1 (en)
EP (1) EP4463456A4 (en)
JP (1) JP2025502172A (en)
CN (1) CN118510778A (en)
TW (1) TW202329955A (en)
WO (1) WO2023134708A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
EP4464709A4 (en) * 2022-01-13 2025-12-24 Nanjing Zaiming Pharmaceutical Co Ltd SIX-MOUNT CYCLOTHIAZOLE COMPOUND AND USES THEREOF
KR20250092184A (en) 2022-10-28 2025-06-23 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 Fused ring nitrogen-containing compounds, intermediates thereof, methods for their preparation and uses
CN120152972A (en) * 2022-11-10 2025-06-13 北京丹擎医药科技有限公司 Thiadiazole derivatives and their compositions and uses
KR20250153866A (en) 2023-03-10 2025-10-27 브레이크포인트 테라퓨틱스 게엠베하 DNA polymerase theta inhibitor
PE20260291A1 (en) 2023-04-05 2026-02-10 Moma Therapeutics Inc SEMI-SATURATED BICYCLE DERIVATIVES AND RELATED USES
AU2024254066A1 (en) * 2023-04-05 2025-10-16 Moma Therapeutics, Inc. Biaryl derivatives and related uses
WO2024230578A1 (en) * 2023-05-05 2024-11-14 Danatlas Pharmaceuticals Co., Ltd. Cyclic derivatives, compositions and uses thereof
CN119306741A (en) * 2023-07-12 2025-01-14 杭州圣域生物医药科技有限公司 Cyclic heteroaromatic compounds, intermediates thereof, preparation methods and applications
CN121532193A (en) * 2023-07-12 2026-02-13 先声再明医药股份有限公司 Use of a compound for the prevention or treatment of cancers with defects in the 53BP1/Shieldin complex.
WO2025113605A1 (en) * 2023-12-01 2025-06-05 Ningbo Newbay Technology Development Co., Ltd. Helicase bicycle amides derivatives and use thereof
CN122295094A (en) * 2023-12-08 2026-06-26 北京丹擎医药科技有限公司 Combination therapy of PolQ inhibitors and anticancer drugs
AU2025205783A1 (en) * 2024-01-05 2026-07-23 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same
WO2025201413A1 (en) * 2024-03-26 2025-10-02 上海湃隆生物科技有限公司 Selenium-containing heterocyclic compound and use thereof
WO2025223472A1 (en) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 Preparation method for fused ring nitrogen-containing compound and intermediate thereof
WO2025223471A1 (en) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 Preparation method for fused-ring nitrogen-containing compound and intermediate thereof
CN122055370A (en) * 2024-04-24 2026-05-15 杭州圣域生物医药科技有限公司 And cyclic nitrogen-containing compound, crystal form thereof, preparation method and application thereof
WO2025223470A1 (en) * 2024-04-26 2025-10-30 杭州圣域生物医药科技有限公司 Use of polq inhibitor in preparation of drug for treating or preventing tumor
WO2026046303A1 (en) * 2024-08-30 2026-03-05 杭州圣域生物医药科技有限公司 COMBINATION OF POLθ INHIBITOR AND PARP INHIBITOR AND USE THEREOF
WO2026067816A1 (en) * 2024-09-30 2026-04-02 正大天晴药业集团股份有限公司 Compound containing thiazolo ring structure
KR20260105834A (en) * 2024-10-11 2026-07-07 아벨로스테라퓨틱스 주식회사 Seleno-fused heterocyclic compound derivatives and their pharmaceutical uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243459A1 (en) * 2019-05-31 2020-12-03 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors
WO2021242955A1 (en) * 2020-05-28 2021-12-02 Senda Biosciences, Inc. Fused azole heterocycles as ahr antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071035A1 (en) * 2004-12-31 2006-07-06 Lg Life Sciences, Ltd. Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives
PE20080888A1 (en) * 2006-10-18 2008-08-26 Novartis Ag HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1)
JP2010138073A (en) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd Picolinic acid amide compound
WO2019141980A1 (en) * 2018-01-17 2019-07-25 Globachem Nv Agricultural chemicals
GB202001181D0 (en) * 2020-01-28 2020-03-11 Globachem Nv Agricultural Chemicals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243459A1 (en) * 2019-05-31 2020-12-03 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors
WO2021242955A1 (en) * 2020-05-28 2021-12-02 Senda Biosciences, Inc. Fused azole heterocycles as ahr antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZATREANU DIANA ET AL: "Pol[theta] inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance", NATURE COMMUNICATIONS, 17 June 2021 (2021-06-17), London, pages 3636 - 3636, XP055847098, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-021-23463-8.pdf> [retrieved on 20211004], DOI: 10.1038/s41467-021-23463-8 *
ZHOU JIA ET AL: "A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors", NATURE CANCER, vol. 2, no. 6, 17 June 2021 (2021-06-17), pages 598 - 610, XP093087790, Retrieved from the Internet <URL:https://www.nature.com/articles/s43018-021-00203-x> DOI: 10.1038/s43018-021-00203-x *

Also Published As

Publication number Publication date
US20250026766A1 (en) 2025-01-23
TW202329955A (en) 2023-08-01
JP2025502172A (en) 2025-01-24
EP4463456A1 (en) 2024-11-20
WO2023134708A1 (en) 2023-07-20
CN118510778A (en) 2024-08-16

Similar Documents

Publication Publication Date Title
EP4216951A4 (en) KRAS-G12D INHIBITORS
IL304334A (en) Modified double-stranded oligonucleotides
EP4197538A4 (en) EGFR INHIBITORS
PL4363406T3 (en) NLRP3 INFLAMASOME INHIBITORS
EP4189086A4 (en) PURIFICATION OF SULFONATED DNA
IL261015B (en) History of methylamine as lysyl oxidase inhibitors for cancer treatment
IL283775A (en) Trilop-containing double-stranded nucleic acid inhibitory molecules
EP4182301C0 (en) AMIDOCYCLOHEXANOIC ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS
EP4149629C0 (en) PURINE DERIVATIVES AS SIK-3 INHIBITORS
EP3946288A4 (en) SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOLE-3-YL-AMINE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS
PL4182308T3 (en) Pyridazinylamine derivatives as ALK5 inhibitors
EP4153596A4 (en) NEW DIACYLGLYCERIDE-O-ACYLTRANSFERASE-2 INHIBITORS
EP4359402C0 (en) IMIDAZOLO-INDAZOLE COMPOUNDS AS JAK Inhibitors
EP4452967A4 (en) SARS-CoV-2 inhibitors
KR102493424B9 (en) RNA detection method
EP4247372A4 (en) PLASMAKALLIK INHIBITORS
EP4281457A4 (en) PYRIDOPYRIMIDE DERIVATIVES AS KRAS INHIBITORS
EP4251273C0 (en) PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS
EP4392415A4 (en) SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
PL4228755T3 (en) TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS
EP4210694A4 (en) PLASMAKALLIK INHIBITORS
EP4178620A4 (en) PLASMAKALLIK INHIBITORS
EP4387965A4 (en) ARYLSULFONYL COMPOUNDS AS CCR6 INHIBITORS
EP4128186A4 (en) REDUCING DRIVING RISK
EP4405334C0 (en) SORTILIN INHIBITORS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240708

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250925

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 471/04 20060101AFI20250919BHEP

Ipc: C07D 487/04 20060101ALI20250919BHEP

Ipc: C07D 498/04 20060101ALI20250919BHEP

Ipc: C07D 513/04 20060101ALI20250919BHEP

Ipc: A61K 31/437 20060101ALI20250919BHEP

Ipc: A61P 35/00 20060101ALI20250919BHEP

Ipc: A61K 31/506 20060101ALI20250919BHEP

Ipc: A61K 31/5377 20060101ALI20250919BHEP

Ipc: C07D 401/14 20060101ALI20250919BHEP

Ipc: C07D 413/14 20060101ALI20250919BHEP

Ipc: C07D 417/14 20060101ALI20250919BHEP

Ipc: C07D 519/00 20060101ALI20250919BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BEONE MEDICINES I GMBH